CAR T: FAQ
CAR T Cell Therapy for Lymphoma, Leukemia, and Myeloma: Experts Answer Clinician Questions

Released: September 14, 2020

Expiration: September 13, 2021

Michael R. Bishop
Michael R. Bishop, MD
Daniel J. DeAngelo
Daniel J. DeAngelo, MD, PhD
Noopur Raje
Noopur Raje, MD

Activity

Progress
1
Course Completed

In this episode, Michael R. Bishop, MD; Daniel J. DeAngelo, MD, PhD; and Noopur Raje, MD, answer clinician questions on current best practices and emerging applications with CAR T-cell therapy, with topics including:

  • Optimal use of approved CAR T-cell therapies for lymphoma and ALL
  • Investigational CAR T-cell therapies for multiple myeloma
  • Managing CAR T-cell therapy–related toxicities

Content based on an online CME program supported by educational grants from Celgene Corporation and Legend Biotech USA Inc.

Link to full program: https://www.clinicaloptions.com/oncology/programs/car-tcell-therapy